<p>CG Oncology, Inc.（纳斯达克代码：CGON - 获取免费报告）的股票在目前覆盖该公司的十五位分析师中被给予了 “适度买入” 的平均推荐，Marketbeat.com 报道。一位分析师对该股票给予了卖出推荐，两位给予了持有推荐，十一位给予了买入推荐，还有一位给予了强烈买入推荐。在过去一年中，对该股票发布评级的经纪公司平均十二个月目标价为 60.5833 美元。</p>
<ul>
<li>发现 2024 年表现最佳的三只生物科技 IPO 股票</li>
</ul>
<p>多位分析师对 CGON 股票发表了评论。摩根大通将 CG Oncology 的股票目标价从 41.00 美元上调至 47.00 美元，并在 9 月 26 日的研究报告中给予该公司 “增持” 评级。华尔街 Zen 在 10 月 3 日的研究报告中将 CG Oncology 的股票评级从 “卖出” 上调至 “持有”。HC Wainwright 在 9 月 15 日的报告中重申了 “买入” 评级，并对 CG Oncology 的股票设定了 75.00 美元的目标价。Wedbush 在周四开始对 CG Oncology 的股票进行覆盖，给予了 “跑赢大盘” 评级和 70.00 美元的目标价。最后，加拿大皇家银行在 11 月 17 日的报告中将 CG Oncology 的股票目标价从 53.00 美元上调至 61.00 美元，并给予了 “跑赢大盘” 评级。</p>
<p><strong>查看我们对 CG Oncology 的最新分析</strong></p>
<h2>内部人士买卖情况</h2>
<p>在相关消息中，董事 James Mulay 在 9 月 18 日的交易中出售了 19,112 股该股票。该股票以 39.01 美元的平均价格出售，总交易额为 745,559.12 美元。此次出售在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，董事 Leonard E. Post 在 9 月 30 日的交易中出售了 5,000 股该公司的股票。该股票以 40.09 美元的平均价格出售，总交易额为 200,450.00 美元。有关此次出售的更多细节可在官方 SEC 披露中找到。过去三个月，内部人士共出售了价值 1,886,331 美元的 47,344 股公司股票。</p>
<h2>机构投资者对 CG Oncology 的看法</h2>
<p>几家机构投资者和对冲基金最近买卖了该公司的股票。查尔斯·施瓦布投资管理公司在第一季度将其在 CG Oncology 的持仓增加了 2.7%。查尔斯·施瓦布投资管理公司目前拥有 439,278 股该公司的股票，价值 10,758,000 美元，此前在上一季度又购买了 11,518 股。瑞士国家银行在第一季度将其在 CG Oncology 的股份增加了 1.9%。瑞士国家银行目前拥有 81,100 股该公司的股票，价值 1,986,000 美元，此前在此期间又购买了 1,500 股。景顺公司在第一季度将其在 CG Oncology 的持股增加了 2.5%。景顺公司目前拥有 27,754 股该公司的股票，价值 680,000 美元，此前在上一季度又购买了 685 股。Nuveen LLC 在第一季度购买了 CG Oncology 的新头寸，价值约为 4,084,000 美元。最后，Fox Run Management L.L.C.在第一季度获得了 CG Oncology 的新股份，价值 408,000 美元。机构投资者持有该公司 26.56% 的股票。</p>
<h2>CG Oncology 股价下跌 1.6%</h2>
<p>CG Oncology 的股票周一开盘价为 40.94 美元。CG Oncology 的 52 周最低价为 14.80 美元，52 周最高价为 46.01 美元。该股票的市值为 33 亿美元，市盈率为-20.07，贝塔值为 1.29。该公司的 50 日移动平均价格为 42.01 美元，200 日移动平均价格为 33.36 美元。</p>
<p>CG Oncology（纳斯达克代码：CGON - 获取免费报告）最近在 11 月 14 日发布了季度财报。该公司报告每股收益（EPS）为-0.57 美元，符合市场共识预期的-0.57 美元。该公司季度收入为 16 万美元，而分析师预期为 7 万美元。CG Oncology 的净利润率为-15,945.17%，股本回报率为-21.67%。平均而言，股票分析师预测 CG Oncology 在当前财年将发布-1.31 的每股收益。</p>
<h2>关于 CG Oncology</h2>
<p>（获取免费报告）</p>
<p>CG Oncology, Inc.是一家专注于开发和商业化肿瘤免疫疗法的公司，致力于为膀胱癌患者开发基础的膀胱保护治疗。该公司开发 BOND-003 用于治疗高风险的卡介苗（BCG）无反应非肌肉侵袭性膀胱癌（NMIBC）患者；CORE-001 用于与帕博利珠单抗联合治疗高风险 BCG 无反应 NMIBC 患者；CORE-002 用于与免疫检查点抑制剂 nivolumab 联合治疗肌肉侵袭性膀胱癌患者。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过 CG Oncology</li>
<li>哪些华尔街分析师最准确？</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了游戏</li>
<li>投资者如何从盘后交易中获益</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>什么是股息收割策略，投资者如何从中获利？</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dPTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dPTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 CG Oncology 吗？</h2>
<p>在考虑 CG Oncology 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 CG Oncology 并不在名单上。</p>
<p>虽然 CG Oncology 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CGON

<p>CG Oncology, Inc.（纳斯达克代码：CGON）的股票获得了十五位分析师的 “适度买入” 平均评级。平均十二个月目标价为 60.58 美元。最近的分析师评级包括摩根大通的 “增持”，目标价为 47 美元，HC Wainwright 的 “买入”，目标价为 75 美元，以及加拿大皇家银行的 “跑赢大盘”，目标价为 61 美元。内部交易包括董事 James Mulay 和 Leonard E. Post 的股票出售。机构投资者持有该股票的 26.56%。CG Oncology 报告第三季度每股收益为（0.57 美元），收入为 16 万美元</p>

<p>Shares of CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) have been assigned an average recommendation of &#34;Moderate Buy&#34; from the fifteen analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eleven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $60.5833.</p>
<div class="lb-trans"><p>CG Oncology, Inc.（纳斯达克代码：CGON - 获取免费报告）的股票在目前覆盖该公司的十五位分析师中被给予了 “适度买入” 的平均推荐，Marketbeat.com 报道。一位分析师对该股票给予了卖出推荐，两位给予了持有推荐，十一位给予了买入推荐，还有一位给予了强烈买入推荐。在过去一年中，对该股票发布评级的经纪公司平均十二个月目标价为 60.5833 美元。</p>
</div><ul>
<li>Discover the 3 Best-Performing Biotech IPO Stocks of 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>发现 2024 年表现最佳的三只生物科技 IPO 股票</li>
</ul>
</div><p>A number of analysts have commented on CGON shares. JPMorgan Chase &amp; Co. upped their price objective on shares of CG Oncology from $41.00 to $47.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, September 26th. Wall Street Zen raised shares of CG Oncology from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Friday, October 3rd. HC Wainwright restated a &#34;buy&#34; rating and issued a $75.00 price objective on shares of CG Oncology in a report on Monday, September 15th. Wedbush started coverage on shares of CG Oncology in a research report on Thursday. They issued an &#34;outperform&#34; rating and a $70.00 target price for the company. Finally, Royal Bank Of Canada raised their price target on shares of CG Oncology from $53.00 to $61.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, November 17th.</p>
<div class="lb-trans"><p>多位分析师对 CGON 股票发表了评论。摩根大通将 CG Oncology 的股票目标价从 41.00 美元上调至 47.00 美元，并在 9 月 26 日的研究报告中给予该公司 “增持” 评级。华尔街 Zen 在 10 月 3 日的研究报告中将 CG Oncology 的股票评级从 “卖出” 上调至 “持有”。HC Wainwright 在 9 月 15 日的报告中重申了 “买入” 评级，并对 CG Oncology 的股票设定了 75.00 美元的目标价。Wedbush 在周四开始对 CG Oncology 的股票进行覆盖，给予了 “跑赢大盘” 评级和 70.00 美元的目标价。最后，加拿大皇家银行在 11 月 17 日的报告中将 CG Oncology 的股票目标价从 53.00 美元上调至 61.00 美元，并给予了 “跑赢大盘” 评级。</p>
</div><p><strong>View Our Latest Analysis on CG Oncology</strong></p>
<div class="lb-trans"><p><strong>查看我们对 CG Oncology 的最新分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖情况</h2>
</div><p>In related news, Director James Mulay sold 19,112 shares of the stock in a transaction that occurred on Thursday, September 18th. The stock was sold at an average price of $39.01, for a total transaction of $745,559.12. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, Director Leonard E. Post sold 5,000 shares of the firm's stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $40.09, for a total transaction of $200,450.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 47,344 shares of company stock worth $1,886,331 over the last three months.</p>
<div class="lb-trans"><p>在相关消息中，董事 James Mulay 在 9 月 18 日的交易中出售了 19,112 股该股票。该股票以 39.01 美元的平均价格出售，总交易额为 745,559.12 美元。此次出售在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，董事 Leonard E. Post 在 9 月 30 日的交易中出售了 5,000 股该公司的股票。该股票以 40.09 美元的平均价格出售，总交易额为 200,450.00 美元。有关此次出售的更多细节可在官方 SEC 披露中找到。过去三个月，内部人士共出售了价值 1,886,331 美元的 47,344 股公司股票。</p>
</div><h2>Institutional Investors Weigh In On CG Oncology</h2>
<div class="lb-trans"><h2>机构投资者对 CG Oncology 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. raised its position in CG Oncology by 2.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 439,278 shares of the company's stock worth $10,758,000 after purchasing an additional 11,518 shares in the last quarter. Swiss National Bank grew its stake in shares of CG Oncology by 1.9% in the 1st quarter. Swiss National Bank now owns 81,100 shares of the company's stock valued at $1,986,000 after purchasing an additional 1,500 shares during the period. Invesco Ltd. raised its holdings in shares of CG Oncology by 2.5% in the 1st quarter. Invesco Ltd. now owns 27,754 shares of the company's stock worth $680,000 after buying an additional 685 shares in the last quarter. Nuveen LLC bought a new position in shares of CG Oncology during the 1st quarter worth approximately $4,084,000. Finally, Fox Run Management L.L.C. acquired a new stake in CG Oncology in the 1st quarter valued at $408,000. Institutional investors own 26.56% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近买卖了该公司的股票。查尔斯·施瓦布投资管理公司在第一季度将其在 CG Oncology 的持仓增加了 2.7%。查尔斯·施瓦布投资管理公司目前拥有 439,278 股该公司的股票，价值 10,758,000 美元，此前在上一季度又购买了 11,518 股。瑞士国家银行在第一季度将其在 CG Oncology 的股份增加了 1.9%。瑞士国家银行目前拥有 81,100 股该公司的股票，价值 1,986,000 美元，此前在此期间又购买了 1,500 股。景顺公司在第一季度将其在 CG Oncology 的持股增加了 2.5%。景顺公司目前拥有 27,754 股该公司的股票，价值 680,000 美元，此前在上一季度又购买了 685 股。Nuveen LLC 在第一季度购买了 CG Oncology 的新头寸，价值约为 4,084,000 美元。最后，Fox Run Management L.L.C.在第一季度获得了 CG Oncology 的新股份，价值 408,000 美元。机构投资者持有该公司 26.56% 的股票。</p>
</div><h2>CG Oncology Trading Down 1.6%</h2>
<div class="lb-trans"><h2>CG Oncology 股价下跌 1.6%</h2>
</div><p>Shares of CG Oncology stock opened at $40.94 on Monday. CG Oncology has a 52 week low of $14.80 and a 52 week high of $46.01. The stock has a market cap of $3.30 billion, a PE ratio of -20.07 and a beta of 1.29. The company's 50-day moving average price is $42.01 and its two-hundred day moving average price is $33.36.</p>
<div class="lb-trans"><p>CG Oncology 的股票周一开盘价为 40.94 美元。CG Oncology 的 52 周最低价为 14.80 美元，52 周最高价为 46.01 美元。该股票的市值为 33 亿美元，市盈率为-20.07，贝塔值为 1.29。该公司的 50 日移动平均价格为 42.01 美元，200 日移动平均价格为 33.36 美元。</p>
</div><p>CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.57). The firm had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.07 million. CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 21.67%. On average, equities analysts predict that CG Oncology will post -1.31 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CG Oncology（纳斯达克代码：CGON - 获取免费报告）最近在 11 月 14 日发布了季度财报。该公司报告每股收益（EPS）为-0.57 美元，符合市场共识预期的-0.57 美元。该公司季度收入为 16 万美元，而分析师预期为 7 万美元。CG Oncology 的净利润率为-15,945.17%，股本回报率为-21.67%。平均而言，股票分析师预测 CG Oncology 在当前财年将发布-1.31 的每股收益。</p>
</div><h2>About CG Oncology</h2>
<div class="lb-trans"><h2>关于 CG Oncology</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.</p>
<div class="lb-trans"><p>CG Oncology, Inc.是一家专注于开发和商业化肿瘤免疫疗法的公司，致力于为膀胱癌患者开发基础的膀胱保护治疗。该公司开发 BOND-003 用于治疗高风险的卡介苗（BCG）无反应非肌肉侵袭性膀胱癌（NMIBC）患者；CORE-001 用于与帕博利珠单抗联合治疗高风险 BCG 无反应 NMIBC 患者；CORE-002 用于与免疫检查点抑制剂 nivolumab 联合治疗肌肉侵袭性膀胱癌患者。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than CG Oncology</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>How Can Investors Benefit From After-Hours Trading</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
<li>What is a Dividend Harvesting Strategy and How Can Investors Profit from it?</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 CG Oncology</li>
<li>哪些华尔街分析师最准确？</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了游戏</li>
<li>投资者如何从盘后交易中获益</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>什么是股息收割策略，投资者如何从中获利？</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dPTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CGON"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CG Oncology Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 CG Oncology 吗？</h2>
</div><p>Before you consider CG Oncology, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CG Oncology 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 CG Oncology 并不在名单上。</p>
</div><p>While CG Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CG Oncology 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

CG Oncology, Inc. (NASDAQ:CGON) 被券商给予 “适度买入” 的平均评级